DNTH103
Healthy Volunteers (SAD/MAD)
Key Facts
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotech company focused on developing precision monoclonal antibody therapeutics for autoimmune diseases. Its core strategy is the selective inhibition of the classical complement pathway via its lead candidate, DNTH103, which targets C1s. The company went public in 2024, securing capital to advance its pipeline through clinical trials. Its mission is to address unmet needs in autoimmune care by developing therapies with potentially superior safety and tolerability compared to broad immunosuppressants.
View full company profileAbout Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotech company focused on developing precision monoclonal antibody therapeutics for autoimmune diseases. Its core strategy is the selective inhibition of the classical complement pathway via its lead candidate, DNTH103, which targets C1s. The company went public in 2024, securing capital to advance its pipeline through clinical trials. Its mission is to address unmet needs in autoimmune care by developing therapies with potentially superior safety and tolerability compared to broad immunosuppressants.
View full company profile